Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal and chronic wounds, has announced terms for its $75 million IPO. The Petach Tikva company is offering 5.4 million shares, according to Renaissance Capital Investments.

Macrocure’s main product is CureXcell, a cell based therapy that when applied to a wound, restores the natural balance required for the wound healing process.

CureXcell has been approved as a medical device in Israel and has been used in more than 5,000 patients in commercial or clinical study settings with consistent results, according to Macrocure data.